Switch theme
Sign up to access all valuation multiples
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceuticals pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
2015
181
LTM Revenue $4.9M
LTM EBITDA -$21.8M
$50.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nanoform has a last 12-month revenue (LTM) of $4.9M and a last 12-month EBITDA of -$21.8M.
In the most recent fiscal year, Nanoform achieved revenue of $3.1M and an EBITDA of -$22.7M.
Nanoform expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nanoform valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.9M | XXX | $3.1M | XXX | XXX | XXX |
| Gross Profit | $4.1M | XXX | $2.5M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | -$21.8M | XXX | -$22.7M | XXX | XXX | XXX |
| EBITDA Margin | -446% | XXX | -727% | XXX | XXX | XXX |
| EBIT | -$25.6M | XXX | -$27.2M | XXX | XXX | XXX |
| EBIT Margin | -523% | XXX | -871% | XXX | XXX | XXX |
| Net Profit | -$24.7M | XXX | -$26.3M | XXX | XXX | XXX |
| Net Margin | -505% | XXX | -843% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nanoform's stock price is EUR 1 (or $1).
Nanoform has current market cap of EUR 76.8M (or $86.3M), and EV of EUR 45.1M (or $50.7M).
See Nanoform trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $50.7M | $86.3M | XXX | XXX | XXX | XXX | $-0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nanoform has market cap of $86.3M and EV of $50.7M.
Nanoform's trades at 16.3x EV/Revenue multiple, and -2.2x EV/EBITDA.
Equity research analysts estimate Nanoform's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nanoform has a P/E ratio of -3.5x.
See valuation multiples for Nanoform and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $86.3M | XXX | $86.3M | XXX | XXX | XXX |
| EV (current) | $50.7M | XXX | $50.7M | XXX | XXX | XXX |
| EV/Revenue | 10.4x | XXX | 16.3x | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | -2.2x | XXX | XXX | XXX |
| EV/EBIT | -2.0x | XXX | -1.9x | XXX | XXX | XXX |
| EV/Gross Profit | 12.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.5x | XXX | -3.3x | XXX | XXX | XXX |
| EV/FCF | -2.5x | XXX | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNanoform's last 12 month revenue growth is 121%
Nanoform's revenue per employee in the last FY averaged $17K, while opex per employee averaged $0.2M for the same period.
Nanoform's rule of 40 is -575% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nanoform's rule of X is -144% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nanoform and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 121% | XXX | 125% | XXX | XXX | XXX |
| EBITDA Margin | -446% | XXX | -727% | XXX | XXX | XXX |
| EBITDA Growth | -23% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -575% | XXX | -606% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -144% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $17K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 951% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| D&D Pharmatech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanoform acquired XXX companies to date.
Last acquisition by Nanoform was XXXXXXXX, XXXXX XXXXX XXXXXX . Nanoform acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nanoform founded? | Nanoform was founded in 2015. |
| Where is Nanoform headquartered? | Nanoform is headquartered in Finland. |
| How many employees does Nanoform have? | As of today, Nanoform has 181 employees. |
| Who is the CEO of Nanoform? | Nanoform's CEO is Dr. Edward Haeggstrom. |
| Is Nanoform publicy listed? | Yes, Nanoform is a public company listed on HEL. |
| What is the stock symbol of Nanoform? | Nanoform trades under NANOFH ticker. |
| When did Nanoform go public? | Nanoform went public in 2020. |
| Who are competitors of Nanoform? | Similar companies to Nanoform include e.g. LTR Pharma, Starpharma, Schott Pharma, Peptron. |
| What is the current market cap of Nanoform? | Nanoform's current market cap is $86.3M |
| What is the current revenue of Nanoform? | Nanoform's last 12 months revenue is $4.9M. |
| What is the current revenue growth of Nanoform? | Nanoform revenue growth (NTM/LTM) is 121%. |
| What is the current EV/Revenue multiple of Nanoform? | Current revenue multiple of Nanoform is 10.4x. |
| Is Nanoform profitable? | Yes, Nanoform is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nanoform? | Nanoform's last 12 months EBITDA is -$21.8M. |
| What is Nanoform's EBITDA margin? | Nanoform's last 12 months EBITDA margin is -446%. |
| What is the current EV/EBITDA multiple of Nanoform? | Current EBITDA multiple of Nanoform is -2.3x. |
| What is the current FCF of Nanoform? | Nanoform's last 12 months FCF is -$20.3M. |
| What is Nanoform's FCF margin? | Nanoform's last 12 months FCF margin is -416%. |
| What is the current EV/FCF multiple of Nanoform? | Current FCF multiple of Nanoform is -2.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
